1.Periodic Assessment of Antenatal and Post Natal Serum Endothelin-1 (ET-1) and Nitric Oxide (NO) Levels in Hypertensive Disorders of Pregnancy (HDP)
The International Medical Journal Malaysia 2019;18(2):101-106
Introduction: Hypertensive Disorders of Pregnancy (HDP) is an independent risk factor of cardiovascular
(CVS) disease with endothelial dysfunction postulated to be the pathophysiology. Endothelin-1 (ET-1), a
potent vasoconstrictor, has been identified as a pivotal mediator in HDP. Disturbances in nitric oxide (NO)
bioavailability found in endothelial dysfunction may increase susceptibility to cardiovascular diseases such as
hypertension. The study aims to determine serial ET-1 and NO levels in patients with HDP and its role in
persistent endothelial dysfunction. Materials and Methods: Thirty-six pregnant women from the following
categories (i) normal pregnant women (Control) (ii) chronic hypertension during pregnancy (CH) and (iii)
pregnancy induced hypertension (PIH) participated in this study. Blood pressure indices measurements and
sample collection were done at antepartum (32 weeks) and postpartum (8 weeks and 12 weeks). ET-1 and
serum NO were measured using the Human ET-1 (Endothelin-1) ELISA Kit and Nitric Oxide (total) detection
kit respectively. Results: Serum ET-1 was significantly higher in patients with CH (55.3 pg/ml) and PIH (35.6
pg/ml) compared to Control (11.8 pg/ml) during antenatal until 3 months postpartum (CH 38.3 pg/ml, PIH
29.5 pg/ml, Control 1.9 pg/ml). This was accompanied by significantly lower levels of serum NO in HDP
patients. Conclusion: Persistently higher than normal levels of ET-1 and lower than normal levels of NO up to
3 months postpartum in patients with history of HDP indicate presence of persistent endothelial dysfunction
despite BP normalisation in PIH patients. Long term NO/ET-1 imbalance may account for the increased CVS
disease risk.
2.Validity and reliability of the Patient Activation Measure® (PAM®)-13 Malay version among patients with Metabolic Syndrome in primary care
Anis Safura Ramli ; Nur Hidayah Bahrom ; Mohamad Rodi Isa ; Noorhida Baharudin ; Siti Fatimah Badlishah Sham ; Mohamed Syarif Mohamed Yassin ; Hasidah Abdul Hamid
Malaysian Family Physician 2020;15(3):22-34
Introduction: The Patient Activation Measure (PAM) is one of the most extensively used, widely
translated, and tested instruments worldwide in measuring patient activation levels in self-management.
This study aimed to determine the validity and reliability of the PAM-13 Malay version among patients
with Metabolic Syndrome (MetS) attending a primary care clinic.Methods: This work is a cross-sectional validation study among patients with MetS attending a
university primary care clinic in Selangor. The PAM-13 Malay version underwent a validation process
and field testing. Psychometric properties were examined using principal component analysis (PCA)
with varimax rotation, scree plot, Monte Carlo simulation, internal consistency, and test-retest
reliability analyses.
Results: The content of the PAM-13 Malay version and the original version were conceptually
equivalent. The questionnaire was refined after face validation by 10 patients with MetS. The refined
version was then field-tested among 130 participants (response rate 89.7%). The Kaiser–Meyer–
Olkin test was 0.767, and Bartlett’s test of sphericity was ≤0.001, indicating sampling adequacy. Two
factors were identified and labeled as (1) Passive and Building Knowledge, and (2) Taking Action and
Maintaining Behavior. These labels were chosen as they were conceptually consistent with the items
representing the levels of activation in PAM-13. The validated PAM-13 Malay version consisted of
13 items, framed into two domains. The overall Cronbach’s α was 0.79, and the intraclass correlation
coefficient was 0.45.
Conclusions: The PAM-13 Malay version is valid, reliable, and fairly stable over time. This
questionnaire can be used to evaluate the levels of activation among patients with MetS in primary care in Malaysia.